DUBLIN, April 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24^th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc

Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:

Jamie Constantine

Investor Relations

+1 781 873 2402

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-302418938.html

SOURCE Alkermes plc